Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world

ConclusionsAdvanced gastric cancer patients with a favourable ECOG performance status, lower LDH levels, and a lower neutrophils/lymphocytes ratio at the start of second-line therapy seem to have better outcomes, regardless of age and intensity of treatment. A longer progression-free survival in the first-line therapy also had positive prognostic value. Our real-life study might help clinicians to identify the patients who may benefit most from a second-line therapy.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research